Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency

BACKGROUND. The histone deacetylase (HDAC) inhibitor vorinostat (VOR) can increase HIV RNA expression in vivo within resting CD4(+) T cells of aviremic HIV(+) individuals. However, while studies of VOR or other HDAC inhibitors have reported reversal of latency, none has demonstrated clearance of lat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Invest
Autors principals: Archin, Nancie M., Kirchherr, Jennifer L., Sung, Julia A.M., Clutton, Genevieve, Sholtis, Katherine, Xu, Yinyan, Allard, Brigitte, Stuelke, Erin, Kashuba, Angela D., Kuruc, Joann D., Eron, Joseph, Gay, Cynthia L., Goonetilleke, Nilu, Margolis, David M.
Format: Artigo
Idioma:Inglês
Publicat: American Society for Clinical Investigation 2017
Matèries:
Clinical Medicine
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5531421/
https://ncbi.nlm.nih.gov/pubmed/28714868
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI92684
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars